Skip to main content
MDxHealth SA logo

MDxHealth SA — Investor Relations & Filings

Ticker · MDXH ISIN · BE0974461940 LEI · 549300J3MG9F9B5FY646 BR Human health and social work activities
Open in API
Filings indexed 940 across all filing types
Latest filing 2026-04-03 Regulatory Filings
Country BE Belgium
Listing BR MDXH

About MDxHealth SA

https://mdxhealth.com/

MDxHealth SA is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize the diagnosis and treatment of urologic conditions. The company's portfolio of tests is designed to assist clinicians in making more informed decisions. For prostate cancer, its products include Select mdx, which assesses a patient's risk to help determine if a biopsy can be safely avoided; Confirm mdx, which addresses biopsy sampling errors; and the GPS (Genomic Prostate Score) test, a genomic assay that helps guide treatment decisions for men with localized disease. Additionally, the company offers Resolve mdx, a test that aids in selecting appropriate treatment for patients presenting with symptoms of urinary tract infections (UTIs).

Recent filings

Filing Released Lang Actions
S-8 - MDxHealth SA (0001872529) (Filer)
Regulatory Filings Classification · 95% confidence The document is a filing fee calculation table for an S-8 registration statement, which relates to the registration of securities under the Securities Act of 1933. It details the number of shares, offering price, and registration fee. This is a regulatory filing related to securities registration and does not contain financial statements, management discussion, or other report content. The document length is short (1653 characters) and is primarily a fee calculation table, not a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-03 English
3 - MDxHealth SA (0001872529) (Issuer)
Director's Dealing
2026-03-19 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, MDxHealth SA. It reports on acquisitions and amendments to acquisition agreements, including financial statements of the acquired company as exhibits. The document includes audited financial statements of Exosome Diagnostics, Inc. as an exhibit and unaudited pro forma financial information. The Form 6-K is a periodic report used by foreign private issuers to disclose material information. The content focuses on acquisition activity and related financial disclosures rather than a full annual or quarterly report. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. The primary purpose is to report acquisition-related information and financial statements as part of a regulatory filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-02-11 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release attached as Exhibit 99.1 dated January 12, 2026. The document explicitly states that the information is being furnished and not filed, and it is a report pursuant to the Securities Exchange Act of 1934. The document length is 2161 characters, which is relatively short and mainly serves as a cover report for the attached press release. There is no substantive financial data or detailed report content within this text itself. According to the rules, such a document is a regulatory filing that does not contain the full report but rather furnishes information, so it should be classified as Regulatory Filings (RNS).
2026-01-12 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It is a registration statement for the offering and sale of securities, specifically ordinary shares, with a shelf registration allowing up to $200 million in offerings. The text includes details about the registration process, prospectus summary, risk factors, and legal disclaimers typical of a securities registration statement. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a brief notice.
2025-12-29 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.